Prof. Colin Chan

Medical Monitor Azura Clinical Trial at Azura Ophthalmics

Prof. Colin Chan is a Clinical Associate Professor at the University of Sydney since April 2008, serving as Program Director for Ophthalmology Non Award Courses and the Cataract and Refractive Surgery Diploma, in addition to working as a Clinical Senior Lecturer. Since May 2022, Prof. Chan has held the position of Adjunct Associate Professor at The Chinese University of Hong Kong and has been an Adjunct Professor at the University of Canberra since December 2017. An ophthalmic surgeon at Vision Eye Institute since April 2006, Prof. Chan also contributes to various committees within the Royal Australian and New Zealand College of Ophthalmologists. Engagements with multiple organizations include serving on advisory boards for companies such as Alcon, Novartis, and SUN PHARMA focused on dry eye disease. Prof. Chan is pursuing a Masters of Philosophy at the University of Sydney, following a Bachelor of Medicine, Bachelor of Surgery with honours from the University of Melbourne and an early education at Xavier College.

Location

Sydney, Australia

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Azura Ophthalmics

1 followers

Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.


Industries

Employees

11-50

Links